NEWS R E L E A S E

Ocumetics Receives Ethics Committee Approval for First-In-Human Clinical Study of Accommodating Intraocular Lens

For Immediate Release

Calgary, Alberta – July 30, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that the ethics committee of the clinical site in Mexico City overseeing the first in-human study of the Ocumetics accommodating intraocular lens (the “Ocumetics Lens”) has verbally approved the protocol for the study. Formal written approval is expected by August 5, 2025.

Dean Burns, CEO of Ocumetics, commented, “Receiving ethics committee approval is a defining moment in Ocumetics’ 18-year journey to revolutionize vision care. With this green light, we are poised to move forward with the first clinical use of the Ocumetics Lens - a technology designed to provide patients undergoing cataract surgery with the ability to see distant and near objects clearly without the aid of glasses or contact lenses. This marks the historic beginning of a new chapter in ophthalmology.”

The approved clinical study protocol outlines the clinical procedures, safety monitoring activities, inclusion criteria, exclusion criteria, and study endpoints necessary to launch this landmark investigation. Ethics committee approval confirms that the study meets rigorous international standards for patient safety, scientific integrity, and ethical principles.

The study will be conducted in collaboration with an internationally recognized regulatory consulting group, which played a vital role in protocol development and submission to regulatory agencies.

Dean Burns continues, “We are thrilled to reach this important milestone for Ocumetics. The ethics committee’s approval reflects both the strength of the protocol and the readiness of the clinical team. This study represents a major leap forward in innovative intraocular lens development, and we’re honored to be part of it.”

With ethics approval now secured, Ocumetics will proceed with patient recruitment in preparation for the first human implantation.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns	Roger Jewett
President and Chief Executive Officer	Chief Financial Officer
(817) 874-7564	roger.jewett@ocumetics.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Company mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.